Member Info for gjbrandon

Thanks Pilgrim.

£3m debt facility

No dilution to shareholders at a discount

Funding aligned to our growth pace and COVID-19 real-time sensor project well into 2021

Initial drawdown is £1.5m

No loan repayments until 2021

Lender can convert £950,000 at 2.97p

Warrants of 25% of drawdown (£375,000) exercisable at 30% Premium to share price on the date of grant

£3m debt facility

No dilution to shareholders at a discount

Funding aligned to our growth pace and COVID-19 real-time sensor project well into 2021

Initial drawdown is £1.5m

No loan repayments until 2021

Lender can convert £950,000 at 2.97p

Warrants of 25% of drawdown (£375,000) exercisable at 30% Premium to share price on the date of grant

@Stuofthetoon I suspect rather than a catch all solution it will be necessary to have a toolkit with a variety of items that fill in the gaps.

For instance, take the US planning 3m tests a day. That is still less than 1 percent of population. So let's say 50% would take a test, it would mean everyone would get tested roughly once every six months.

So it is likely that if you can highlight areas where hotspots of the virus are, you can lower the requirement to test and thus target a higher percentage at risk, rather than test everyone.

The same with samples from sewage. Multiple novel sensors spread across a county/city sewers would give it a better chance to capture initially that the virus exists, then multiple samples will give the data as to where it is originating from.

The problem today is that samples are taken once/twice a week and not all the time, so it is still a hit and miss. It will confirm that the virus is there but no data to pinpoint the source in time to avoid a spread, merely just to give advance warning to health department to prepare

@MoneyMan not to put too fine a point on it, but RNS's have a value for company promotions of the services to clients as it gets picked up by media and is not published just for traders. Orders and figures are in the interims and guidance remains the same until further notice

@Steven.P it wouldb e worth taking a look at the RNS here we put out on the 3rd June

https://www.londonstockexchange.com/news-article/SKIN/labskin-anti-viral-covid19-skin-and-dental-tests/14562887

This got out earlier than we expected on embargo so I am putting the link here also https://www.cosmeticsbusiness.com/news/article_page/Labskin_launches_remote_clinical_skin_trials_in_a_Covid-19_world/168180

Release on Labskin page https://www.labskin.co.uk/remote-clinical-skin-trials/

This changes the face of Clinical Trials as human volunteers no longer need to leave their homes, whether because of the risk of COVID-19 or unable to get access to remote immunosuppressed volunteers.

We will report news on mouthwash, nasal mucosa skin and normal skin when we have it ready. It's not something we can just get a result and out comes an RNS ?? they have to test, test again and then retest compared to control substances, measure, verify and then report.

I can't comment on who we are working with and contrary to what many believe about this or that company or grant support agency, the reality is that there are other parties and funders with conflicting agendas, restrictions and even conditions that are not beneficial to shareholders if we fund it at the behest of third party benefactors. As they say,, no such thing as a free lunch"

Just wanted to say that this is for a good idea and no doubt there are some interesting ideas out there, but we had this idea 4 years ago and spent that time to get it to work. With Avacta and Aptamer Diagnostics we have the last part of the conversion to capture pathogenic targets. This is tweaking, not a concept or idea, but a unit that is near completion with testing underway

@Chesh Alltracel was a warm up :)

@Chesh

in a previous company (Alltracel) in 2003 my management team had diddly-squat funding and zero sales, yet by 2005 we had 50+ partners in 43 countries, distribution in 300,000 outlets and production in Shenzhen, China, Taipei, Taiwan, Mexico City, Mexico and sub-contracted producers in Italy, Czech Republic and France and turnover of £33m throwing off £2.5 EBITDA. That company sold for $55m in debt and equity in 2008.

Today, Integumen has sales, has invested in production in York for increased production of core bacteria and has been out-sourcing for products and services we need. The recent audit working capital report had no material uncertainty and loan facilities were made available.

I will never forget a presentation in 1997 when (obvious to many of us now) when I realised that 20% of £100m is so much better than 100% of £10m. We don't and won't own 100% of margins and would require substantial investments to do so, but we are very happy to own a large enough slice of a very large pie.

I think everyone needs to calm down a little on this timing issue. There are now hundreds of projects with every PhD and post grad student jumping down manholes and collecting samples and running back to laboratories to undertake a qPCR test to verify that SARS-CoV-2 is in the sewage. And as well as the manpower and transportation to do that if you are realistic it can take anywhere from 10 to 72 hours to process the information, but which time the potential for isolation may well be long gone.

As has been stated. Integumen (Rinocloud) has spent (now) 5 years developing a real-time pathogenic detection system using nanotechnology photonics and AI to perfect the identification and alert when pathogens pass through the system. It was originally designed for bacteria (e.coli)

Now, rather than perfect a virus capturing system, we collaborated with Avacta and Aptamer Diagnostics, who have perfected over many years their ability to identify their pathogen target and capture it. It's not rocket science to say none of the parties reinvented any wheel. We worked and are working together to complete the miniaturisation of the system so that it can be dropped into any of the projects around the world to help them ALL accelerate their results. This is not a competition, this is a solution for them all.

If anyone has watched the world over the last few months they have seen that we have all pulled together, collaborated, cooperated and supported each other. This is the same in what we are doing with our consortium of partners. It is not simply a supply chain, but a consortium of experts and experienced scientists, engineers, designers, in both industry and academia and sales, marketing and distribution channels that are well thought out and under our control.

Everyone has an opinion, I get that, but no sense fighting about it. Those who have a short term perspective will go elsewhere. Those who stay are part of a bigger, longer term project. It's all for the best, no matter whether you are a trader or a LTH

@DaveT1 it just doesn't quite work like that. Governments and utilities and even the W.H.O. tend to be the last to do something about it. We develop for a specific market that is guaranteed to accept the units without any persuading or tendering or helping to write bids. All of that goes on and months go by. Look at the UK suppliers of PPE. All waiting around offering to supply. What happens? Governments allocate funds to third-parties who go and procure equipment outside of UK. So this is not new territory for management. It will get to the targets you mention, but through distribution channels that we control

@Argylerich just some small outstanding queries being processed and then audit committee meeting. There were 10 subsidiaries and there was a fundamental alteration with liquidations, many of those who would have normally been able to do the accounts of the subsidiaries are not longer there, so it is only a handful of items waiting on to sign off.

@mattynix7 it is not quite a countdown clock. I had overlooked some safety protocols and delivery times for the virus to the labs, so bear with us a couple more weeks, and not to the letter of the day, but moving ahead now. Certainly this quarter, as I have said in the recent video

"Attention passengers. Would anyone who suspects they have COVID19, please use their rear door in the toilet before disembarking. Thank you"

@SloppyGuiseppe Integumen marketing identified air travel as a target sector. It would not catch everyone on the plane, but has the potential to capture through wastewater on long-haul flights. It would not be possible to install them on any planes, as the installation on aircraft is a rigorous, multi-year, testing process and may be available in future designed aircraft.

However, there is nothing stopping a waste-disposal unit at each destination having a real-time Microtox Novel Sensor to detect as the plane disembarks and tested with results before passengers leave the airport baggage hall, for immediate track and trace. Cruise ships we are working through that sector at this time.

@PitseaAbe I can't comment on any future RNS. On the question, as of today, there is an RNS of the 18th March which you can find in the www.integumen.com/investors page in the RNS section (sorry writing this from my phone, so no easy access to copy and paste link) search for Modern Water if you can't see it on first list of RNS.

@PitseaAbe Microtox is the 30 year old Brand of water contamination detection equipment that Modern Water supply and both SKIN and MWG supply the recurring revenue consumables of bioluminesence bacteria that detect the contaminents. I am Chairman of the Board of Modern Water and CEO of Integumen. Aptamers are just one virus detection binding agent which is being run through the SKIN testing protocols. We have others, to be revealed soon and will update with an RNS at that time
Hope that explains it a little clearer?

@lazypunter unfortunately the response is not out of an educated research, but lack thereof. At no point, ever, has there been a statement from either Modern water of Integumen that Microtox is anything other than a bacteria, virus or toxin detection system. It can detect up to 2700 contaminants, but cannot identify them. To say otherwise would be misleading and deceitful.

Integumen have already proven the ability to capture and identify pathogens, such as bacteria. See teh london Stock Exchange RNS of the 20th November 2019 (RNS https://www.londonstockexchange.com/news-article/SKIN/results-of-ai-water-research-project/14314998) The development work currently underway with Aptamers and other SARS-CoV-2 binding agents has been a work in progress for many months, but built on 4 years of development of the novel sensor real-time detection system.

I have always, and will continue to advocate, a thorough undertaking of research into any company that a shareholder/investor intends to inject their hard earned money into, whether that is purely speculative or for long term wealth creation. Please, and I mean this sincerely, do not ask the opinion of anyone, unless you can be 100% sure that they too have undertaken a thorough research of the underlying security.

I don't know anyone in stockopedia. They have never reached out to speak with anyone in my team, so I cannot say with any certainty that they would have sufficient knowledge to render an opinion on the underlying technology of either Modern water or Integumen, but I am happy at any time to direct them to the RNS's that both companies have put out since I was involved to find anything other than a technology platform that has the bandwidth in a sales, marketing and distribution channel that Modern water has built up over 30 years with the Microtox brand.

Please do your research and not rely on anyone else, as they are not investing your money, you are and you are responsible for the decision to invest it.

@TILS39 first of all, being a newbie it can be hard to resist the temptation to chase rainbows, as those who have been in the market for years(even decades) know the power of patience and compound interest. It doesn't matter the size of your holding, which is important to each individual, as a shareholder you expect a lot from your investment. PR and IR does not create wealth, it builds trust and knowledge amongst shareholders, which is why I communicate. I am a shareholder and we, as a collective are stakeholders in this project, which is Integumen.

I maintain an open social media policy. I will be doing a webinar soon. Date to be confirmed and we do put out updates regularly. I am grateful for your trust and faith in what we are doing. Be careful. Do your research, then do more. It's not easy to make money on the stock market consistently, but it can be worth it over time to build a portfolio if you begin early and research, research and research.